Oncology Pipeline: Innovations and Trends

Conference Correspondent

In the November 4 webcast session of the Association for Value-Based Cancer Care (AVBCC) 10th Annual Summit, panelists discussed the near-term innovative agents coming to market in the next year and upcoming cancer pharmaceutical trends.

Doug Long, Vice President of Industry Relations at IQVIA, began the session by discussing the impact of COVID-19. He noted that the pandemic has slowed sales growth and greatly affected the oncology market on a unit basis. However, pharmaceutical companies continue to bring new products to the market, and studies show that 40% of all launches in 2020 were in oncology.

Jeffrey M. Bockman, PhD, Executive Vice President and Oncology Practice Head at Cello Health BioConsulting, said that the COVID-19 pandemic has influenced the amount of money going into healthcare, noting that investment in biopharmaceuticals is at a record high. There has been $24 billion raised in new venture funds in 2020, far above the record set in previous years.

William Roth, Founding Partner of Blue Fin Group, discussed future trends in access and management, noting that patients are experiencing more financial issues, and increasing costs continue to be a concern for payers, policy makers, and patients alike. He stressed that the focus needs to be on both accessibility and affordability. As costs grow, Congress is eyeing reforms to the average sales price (ASP) reimbursement construct and experimenting with value-based models. Value-based payment models, ASP reimbursement, and the International Pricing Index could all see reform.

It is not too late to register for the AVBCC Summit! With more than 40 webcasts and other sessions, the 10-week agenda is packed with timely insights and no-holds-barred debates that you need to understand today’s cancer care ecosystem and trends for the future.

Related Articles